Kailera Names Kathleen Tregoning as Chief Corporate Affairs Officer Ahead of Phase 3 Milestones
KLRA•Kailera named Kathleen Tregoning as Chief Corporate Affairs Officer to lead stakeholder engagement and policy strategies as it advances four clinical-stage obesity therapies including ribupatide in global Phase 3 trials. Tregoning brings 20 years of corporate affairs leadership at Cerevel, Sanofi and Biogen, strengthening Kailera’s communications as regulatory milestones approach.
1. Executive Appointment
Kailera Therapeutics has appointed Kathleen Tregoning as Chief Corporate Affairs Officer to oversee global communications, public policy and stakeholder outreach as the company advances its obesity treatment pipeline. The move aligns with Kailera’s push to support its lead candidate, ribupatide injection (KAI-9531), through Phase 3 trials while expanding its portfolio.
2. Corporate Affairs Expertise
Tregoning offers over two decades of experience steering corporate affairs at leading biopharmaceutical firms. She previously served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, EVP of External Affairs at Sanofi, and SVP of Corporate Affairs at Biogen, where she managed communications, patient advocacy and policy initiatives.
3. Strategic Impact
Her appointment bolsters Kailera’s capacity to engage regulators and payers during critical development stages and to build trust among providers and patient communities. With multiple GLP-1 and multi-receptor candidates in clinical stages, enhanced corporate affairs leadership could support favorable policy environments and facilitate market access upon potential approvals.
